← All trials
NCT06564818
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Mar 31, 2026
- Completion date
- May 31, 2026
- First posted
- Aug 21, 2024
- Last posted
- Aug 21, 2024
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cybin Therapeutics Inc.Lead sponsor
- Cybin Therapeutics Inc.Official
- Worldwide Clinical TrialsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.